Compare HOLO & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOLO | OGEN |
|---|---|---|
| Founded | 2018 | 1996 |
| Country | China | United States |
| Employees | 74 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.3M | 2.8M |
| IPO Year | N/A | 2010 |
| Metric | HOLO | OGEN |
|---|---|---|
| Price | $1.56 | $0.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 402.1K | 38.0K |
| Earning Date | 08-10-2023 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.43 | $0.50 |
| 52 Week High | $7.39 | $1.49 |
| Indicator | HOLO | OGEN |
|---|---|---|
| Relative Strength Index (RSI) | 39.72 | 47.16 |
| Support Level | $1.52 | $0.56 |
| Resistance Level | $1.88 | $0.64 |
| Average True Range (ATR) | 0.10 | 0.03 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 26.32 | 44.17 |
MicroCloud Hologram Inc provides holographic technology services. Its services include holographic light detection and ranging (LiDAR) solutions, holographic LiDAR point cloud algorithms architecture design, technical holographic imaging solutions, holographic LiDAR sensor chip design, and holographic vehicle intelligent vision technology to service customers that provide holographic driver assistance systems (ADAS). The company also provides holographic digital twin technology services for customers and has built a proprietary holographic digital twin technology resource library. MicroCloud's operating segments are: Holographic technology service, which generates maximum revenue, and Holographic solutions. Its revenues are mainly generated in the People's Republic of China (PRC).
Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.